ODI Pharma is a Swedish producer and distributor of medical cannabis products.
The company has distribution contracts representing supply contracts to over 14,000 pharmacies, 100’s of specialty clinics and multiple hospitals.
Sells to over 20 countries in Europe.
The company offers a white-labelling service.
NEWS & PARTNERSHIPS:
2020
The company executed on a 5-year supply agreement covering a minimum of 1,200 KG of medical cannabis products per year with Tilray granting ODI the exclusive right to sell a defined set of ODI and Aphria co-branded products in Poland.
2021
The company launched its cosmetic line kandol with highly CBD-infused skincare products sales online to customers within the EU.
2023
The company sold its kandol skincare brand to Niclas Kappelin.
The company entered into an exclusive collaboration agreement with Synoptis Pharma under which ODI becomes the exclusive supply partner for medicinal cannabis flos products to Synoptis for a period of 5 plus additional optional 3.5 years covering 24 countries in Europe.
2024
The company delivered a smaller shipment in terms of economic value of cannabis products to Switzerland and its leading medical cannabis provider.